Abstract

Background: MicroRNAs have been linked to angiogenesis and could prove to be valuable future therapeutic targets in ischemic cardiovascular diseases.Methods: Ten-week-old male C57Bl/6 mice were subjected to left femoral artery ligation and were treated with microRNA-126 mimic at a dose of 5 mg/kg (Group A, n = 10) or 5 mg/kg microRNA mimic negative control (Group B, n = 10) on days 1, 3, and 7. Laser Doppler imaging was performed to verify successful ligation on day 0 and to evaluate differences in the ischemic-to-normal (I/N) hind limb perfusion ratio on day 28. Muscle tissue expression of microRNA-126 and vascular endothelial growth factor (VEGF) was determined via PCR.Results: Following microRNA-126 mimic administration in Group A subjects, we noted a stepwise increase in I/N hind limb perfusion ratio (Day 0: 0.364 ± 0.032 vs. Day 8: 0.788 ± 0.049 vs. Day 28: 0.750 ± 0.039, p = 0.001). In Group B a stepwise increase in I/N hind limb perfusion ratio was observed (Day 0: 0.272 ± 0.057 vs. Day 8: 0.382 ± 0.020 vs. Day 28: 0.542 ± 0.028, p = 0.074). Muscle tissue expression of microRNA-126 in the ischemic hind limb of Group A was 350-fold lower compared to the ischemic hind limb of Group B (p < 0.001). A higher expression (14.2-fold) of VEGF in the ischemic hind limb of microRNA-126-treated mice compared to that of control group was detected (p < 0.001). A statistically significant negative correlation was noted between microRNA-126 and VEGF tissue expression levels in the ischemic limbs of the entire study population.Conclusion: MicroRNA-126 delivery in the ischemic hind limb of mice improved vascular perfusion with VEGF upregulation.

Highlights

  • Peripheral arterial disease (PAD) caused mainly by atherosclerosis portent significant morbidity, adverse prognosis and even mortality (Aboyans et al, 2018)

  • Following microRNA-126 mimic administration in Group A subjects, we noted a stepwise increase in I/N hind limb perfusion ratio (Day 0: 0.364 ± 0.032 vs. Day 8: 0.788 ± 0.049 vs. Day 28: 0.750 ± 0.039, p 0.001)

  • A statistically significant negative correlation was noted between microRNA-126 and vascular endothelial growth factor (VEGF) tissue expression levels in the ischemic limbs of the entire study population

Read more

Summary

Introduction

Peripheral arterial disease (PAD) caused mainly by atherosclerosis portent significant morbidity, adverse prognosis and even mortality (Aboyans et al, 2018). Scientific interest has been shifted towards epigenomics, and especially non coding RNA-based therapeutic and diagnostic approaches in cardiovascular medicine, including microRNAs (Lu and Thum, 2019; Zheng et al, 2020), since their dysregulated expression has been noted in cardiovascular diseases (Vogiatzi et al, 2018; Siasos et al, 2020) They have been tested in various cardiovascular diseases, namely coronary artery disease, PAD and heart failure (Siasos et al, 2014; Economou et al, 2015; Vogiatzi et al, 2018). MicroRNAs have been linked to angiogenesis and could prove to be valuable future therapeutic targets in ischemic cardiovascular diseases

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call